Articles

Revenue remains about flat at $184 million

One analyst notes “a legitimate uplift in demand for fiber infrastructure to support the growth in AI” — but short covering is likely also at play with shares up 500% in a month.

Sandoz, the generics drugmaker spun off from Novartis, is going to get into making cheap versions of the wildly popular GLP-1 class of drugs to treat diabetes and weight loss. But it may take a while.

No banking or credit card information was included in the theft

The number of Americans who applied for unemployment benefits last week fell sharply to 233,000 and receded from a nearly one-year, suggesting layoffs remain quite low and that the labor market is still in good shape.

Selloff creates cast-offs to jump on.

The company’s stock climbed 6% in premarket trading.

Merck & Co. said Thursday it’s discontinuing a late-stage trial of a treatment for patients with extensive-stage small cell lung cancer after patients experienced a high rate of adverse events.

Under Armour Inc.’s stock rose 7.7% premarket Thursday after the athletic-apparel maker beat Wall Street’s top and bottom-line expectations in its first-quarter results and raised its earnings outlook.

The company is gearing up for the rollout of its doughnuts at McDonald’s restaurants, starting in the Midwest with Chicago.

Analysts are always looking for historical parallels to current conditions. In a new note, UBS points to the third quarter of 2011..

Eli Lilly’s stock was headed for its best day in a year on Thursday, after the drugmaker reported second-quarter earnings that rose well above forecasts, amid strength in sales of its diabetes and obesity treatments, Mounjaro and Zepbound.